Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.97 Consensus PT from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given a consensus recommendation of “Buy” by the nine brokerages that are covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $13.97.

Several brokerages have recently issued reports on VYGR. Citigroup started coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, March 13th. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. Canaccord Genuity Group cut their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 13th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th.

Voyager Therapeutics Trading Down 2.4 %

Voyager Therapeutics stock opened at $3.65 on Thursday. Voyager Therapeutics has a 52 week low of $3.56 and a 52 week high of $10.66. The stock has a market cap of $201.51 million, a price-to-earnings ratio of 5.14 and a beta of 0.99. The company’s 50-day moving average price is $4.51 and its two-hundred day moving average price is $5.65.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. During the same quarter last year, the business earned $1.25 earnings per share. Research analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Voyager Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new position in shares of Voyager Therapeutics in the fourth quarter worth approximately $29,000. Tower Research Capital LLC TRC boosted its stake in Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares during the period. Picton Mahoney Asset Management grew its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after purchasing an additional 2,444 shares in the last quarter. Oxford Asset Management LLP purchased a new position in Voyager Therapeutics during the 4th quarter worth approximately $60,000. Finally, Intech Investment Management LLC acquired a new stake in Voyager Therapeutics during the 3rd quarter valued at $74,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.